Screener
Bicara Therapeutics BCAX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accounts payable and accrued expenses | 11,725 | (2,116) |
| Accounts payable and accrued expenses – related party | (1,354) | 3,279 |
| Operating lease liabilities | (270) | (147) |
| Net cash used in operating activities | (37,508) | (28,106) |
| Investing activities: | ||
| Proceeds from maturities and sales of marketable securities | 101,000 | — |
| Purchase of property and equipment | (60) | — |
| Net cash provided by investing activities | 100,940 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's operating cash flow?
- Bicara Therapeutics (BCAX) reported operating cash flow of -$37.51M in Q1 2026.
- How has Bicara Therapeutics's operating cash flow changed year-over-year?
- Bicara Therapeutics's operating cash flow decreased by 33.5% year-over-year, from -$28.11M to -$37.51M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Bicara Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude